Interlink moves to New York, hopes talent will follow

Share this article:
Interlink Healthcare Communications relocated from Princeton, NJ, to the heart of Manhattan, to make it easier for the shop to recruit top talent, said the agency's president. She now hopes the move will also help her build on recent new business wins.
The new office is five blocks from Grand Central Station. “It will be much easier for us to find top-notch talent now because of New York's larger talent pool,” said Susan Flinn, who runs the agency, part of Interpublic Group's Lowe Healthcare Worldwide, along with Dave Renner, EVP, creative director.
“When [Interlink] was founded in 1996, it made sense to be in Princeton, because the biggest client was Bristol-Myers Squibb,” she said. BMS maintains corporate headquarters in New York City but has sites in Princeton and four other New Jersey towns.
A few of NYC's healthcare goliaths maintain smaller satellites in Princeton to service NJ's “pharma row.” Omnicom's Cline Davis & Mann has CDM Princeton. Havas' Euro network has Euro RSCG Life Catapult. InVentiv's GSW Worldwide, based in Columbus, Ohio, has an office just over the Delaware River, in Newtown, PA.
Some Interlink employees decided not to make the move from Jersey, but just as many did, Flinn said, and since the relocation, new recruits have brought headcount to 37, including eight in the last two months. A new director of client services, Katie Brunner, came on board from LLNS. Interlink, long considered a high-science agency because of its medical staff, also just hired a new medical director, Charlotte Singh, MD.
Share this article:

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.